• Home
  • Search Results
  • Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles.

Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles.

Journal of controlled release : official journal of the Controlled Release Society (2013-06-13)
Dongfei Liu, Luis M Bimbo, Ermei Mäkilä, Francesca Villanova, Martti Kaasalainen, Barbara Herranz-Blanco, Carla M Caramella, Vesa-Pekka Lehto, Jarno Salonen, Karl-Heinz Herzig, Jouni Hirvonen, Hélder A Santos

Nanoparticulate drug delivery systems offer remarkable opportunities for clinical treatment. However, there are several challenges when they are employed to deliver multiple cargos/payloads, particularly concerning the synchronous delivery of small molecular weight drugs and relatively larger peptides. Since porous silicon (PSi) nanoparticles (NPs) can easily contain high payloads of drugs with various properties, we evaluated their carrier potential in multi-drug delivery for co-loading of the hydrophobic drug indomethacin and the hydrophilic human peptide YY3-36 (PYY3-36). Sequential loading of these two drugs into the PSi NPs enhanced the drug release rate of each drug and also their amount permeated across Caco-2 and Caco-2/HT29 cell monolayers. Regardless of the loading approach used, dual or single, the drug permeation profiles were in good correlation with their drug release behaviour. Furthermore, the permeation studies indicated the critical role of the mucus intestinal layer and the paracellular resistance in the permeation of the therapeutic compounds across the intestinal wall. Loading with PYY3-36 also greatly improved the cytocompatibility of the PSi NPs. Conformational analysis indicated that the PYY3-36 could still display biological activity after release from the PSi NPs and permeation across the intestinal cell monolayers. These results are the first demonstration of the promising potential of PSi NPs for simultaneous multi-drug delivery of both hydrophobic and hydrophilic compounds.

Product Number
Product Description

Indomethacin, 98.5-100.5% (in accordance with EP)
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Indomethacin, meets USP testing specifications
Indomethacin, European Pharmacopoeia (EP) Reference Standard